Elicio Therapeutics, Inc.ELTXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank88
5Y CAGR-27.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-27.6%/yr
Long-term compound
Percentile
P88
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 38.69% |
| Q3 2025 | -23.87% |
| Q2 2025 | 11.55% |
| Q1 2025 | -15.73% |
| Q4 2024 | -20.21% |
| Q3 2024 | 18.53% |
| Q2 2024 | 26.35% |
| Q1 2024 | -22.49% |
| Q4 2023 | -90.90% |
| Q3 2023 | 45.63% |
| Q2 2023 | -17.15% |
| Q1 2023 | -11.86% |
| Q4 2022 | -35.09% |
| Q3 2022 | -187.78% |
| Q2 2022 | 139.20% |
| Q1 2022 | -8.99% |
| Q4 2021 | 5.51% |
| Q3 2021 | -44.33% |
| Q2 2021 | -73.41% |
| Q1 2021 | -129.49% |
| Q4 2020 | 193.84% |
| Q3 2020 | -71.37% |
| Q2 2020 | -410.75% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |